| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Heal | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $174.35M | Series E | 10/21/2021 | $4.5M | $134.37M | $0.03 | Undisclosed Investors | ||||
 | HealthTap | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $93.45M | Series B | 11/6/2024 | $28.05M | $44.1M | $0.21 | Undisclosed Investors | ||||
 | Hexagon Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $258.62M | Series C | 7/10/2026 | $50M | $128.86M | $0.57 | Undisclosed Investors | ||||
 | Immune-Onc Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $143.15M | Series B3 | 1/6/2023 | $30M | $262.2M | $2.11 | Triwise Capital, Proxima Ventures | ||||
 | Lumicell | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $119.14M | Series BB | 5/6/2025 | $38.98M | $147.81M | $1.16 | Undisclosed Investors | ||||
 | Nalu | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $331.77M | Series E | 10/9/2024 | $115.06M | $382.56M | $4.85 | Novo Holdings, Gilde Healthcare, MVM Partners, Endeavour Vision, Decheng Capital, Longitude Capital, Advent Life Sciences, Pura Vida, Aperture Venture Partners, B Capital | ||||
 | Noyo | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $61.51M | Series B-2 | 5/19/2022 | $22.09M | $310.32M | $9.30 | Norwest Venture Partners, Workday Ventures, Gusto, Cap Table Coalition, Costanoa Ventures, Spark Capital, Homebrew, Operator Collective, Fika Ventures, Precursor Ventures, Garuda Ventures, Core Innovation Capital, Webb Investment Network | ||||
 | Ostro | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $68.67M | Series B-1 | 4/23/2025 | $5.75M | $90.55M | $2.17 | Havas | ||||
 | Prosetta Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $63.64M | Series D | 12/31/2015 | $31.1M | $378.68M | $4.50 | Takeda Ventures, Alger | ||||
 | Rapport Therapeutics | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $250.18M | Series B | 8/7/2023 | $150M | $409.19M | $1.68 | Cormorant Asset Management, Fidelity Management & Research Company, Goldman Sachs Asset Management, Logos Capital, Perceptive Advisors, Sofinnova Investments, Surveyor Capital, Third Rock Ventures, ARCH Venture Partners, Johnson & Johnson Innovation | ||||
 | Ratio Therapeutics | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $151.27M | Series C | 7/31/2026 | $70M | $398.34M | $43.69 | Duquesne Family Office, Bristol Myers Squibb, Catalio Capital Management, Eli Lilly and Company, Wasatch Group | ||||
 | Recludix Pharma | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $123.5M | Series B | 1/12/2026 | $21.5M | $327.7M | $2.31 | Access Biotechnology, Alexandria Venture Investments, NEA, Westlake Village BioPartners, Eli Lilly | ||||
| ROME Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $199M | Series B | 9/24/2021 | $149M | $321.94M | $1.49 | Johnson & Johnson Innovation, Bristol Myers Squibb, Eurofarma Ventures, Luma Group, Mirae Asset Capital, Raycap, Sigmas Group, ARCH Ventures, GV, Section 32, Sanofi Ventures, Andreessen Horowitz, Mass General Brigham Ventures, Casdin Capital, Alexandria Venture Investments | ||||
 | Sapience Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $63.88M | Series B | 5/31/2022 | $28.25M | $289.73M | $3.60 | NexPoint, Bristol Myers Squibb, Eshelman Ventures, Kingdon Capital | ||||
 | Septerna | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $225M | Series B | 7/11/2023 | $150M | $313.42M | $1.23 | RA Capital Management, Third Rock Ventures, Samsara BioCapital, Invus, Catalio Capital Management, BVF Partners, Casdin Capital, Logos Capital, Deep Track Capital, Goldman Sachs Asset Management, Vertex Ventures HC, Mirae Asset Financial Group, Direhaus Capital Management, Woodline Partners LP, Soleus Capital | ||||
 | SynDevRx | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $52.6M | Series C | 9/30/2024 | $29.35M | $270.23M | $7.23 | Undisclosed Investors | ||||
 | TMRW Life Sciences | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $238.98M | Series E | 3/26/2026 | $25.11M | $75.5M | $0.04 | Undisclosed Investors | ||||
 | Adaptive Innovations | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $60M | Series A | 6/2/2026 | $50M | $242.97M | $6.26 | Felicis, Optum Ventures, Sunflower Capital, Conviction, BoxGroup, SV Angel, Dorm Room Fund, Constellation, Bain Capital Ventures | ||||
 | Alloplex Biotherapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $20.67M | Series A | 1/27/2023 | $20.67M | $279.9M | $68.60 | Undisclosed Investors | ||||
 | Allotera Therapeutics | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $322.92M | Series C | 7/23/2026 | $83.2M | $291.45M | $1.77 | Fidelity, RiverVest Venture Partners, Lightchain Capital, LYZZ Capital, Abingworth, Intermediate Capital Group, Tybourne Capital Management, Aisling Capital Management, BioGenerator Ventures, Sands Capital, Alexandria Venture Investments, Velosity Capital, Falcon Edge Capital | ||||
 | AllStripes | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $67.7M | Series B | 8/24/2021 | $50.3M | $308.52M | $9.62 | Lux Capital, Jazz Venture Partners, Spark Capital, Medidata Solution, McKesson Ventures, Maveron Capital, Arif Nathoo, Leila Zegna | ||||
 | Atsena Therapeutics | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $235.9M | Series C-3 | 4/2/2025 | $60M | $337.46M | $4.13 | Bain Capital, Wellington Management, Lightstone Ventures, Sofinnova Investments, Abingworth, Foundation Fighting Blindness, Hatteras Venture Partners, Osage University Partners, Manning Family Foundation | ||||
 | Bardy Diagnostics | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $84.02M | Series B-1 | 2/14/2020 | $13M | $132.82M | $1.30 | River Cities Capital Funds, SV Health Investors, Health Enterprise Partners | ||||
 | BioTheryX | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $173.09M | Series E | 5/20/2021 | $100M | $348.42M | $5.25 | Farallon Capital Management, Avidity Partners, Deep Track Capital, Irving Investors, Janus Henderson Investors, Lumira Ventures, Point72, Rock Springs Capital, Surveyor Capital, Tekla Capital management, Alexandria Ventur Investors, Wedbush Helthcare Partners | ||||